Shandong University, Jinan, Shandong, China.
Int Immunopharmacol. 2013 Oct;17(2):275-82. doi: 10.1016/j.intimp.2013.05.031. Epub 2013 Jun 19.
Mesenchymal stem cells (MSCs) treatment has been shown to be effective in diabetic nephropathy (DN). However, the mechanisms involved in the renoprotective effects of MSCs have not been clearly demonstrated. Especially, there was no study on the relationship of MSCs and macrophages in diabetic kidney. To explore the effect of MSCs on macrophages in DN, streptozotocin-induced diabetes animals received no treatment or treatment with MSCs (2×10(6), via tail vein) for two continuous weeks. Eight weeks after treatment, physical, biochemical and morphological parameters were measured. Immunohistochemistry for fibronectin (FN), CollagenI, ED-1, monocyte chemoattractant protein-1 (MCP-1) was performed. Expressions of pro-inflammatory cytokines and hepatocyte growth factor (HGF) at gene level and protein level were determined by real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. Blood glucose, urinary albumin excretion, creatinine clearance were significantly reduced after MSCs treatment. The glomerulosclerosis as revealed by periodic acid Schiff stain and expression of FN and CollagenI was also dramatically attenuated. Most importantly, the expression of MCP-1 and the number of infiltrated macrophages in kidney were effectively suppressed by MSCs treatment. The expression of HGF in MSCs group was up-regulated. Meanwhile, the expressions of IL-1β, IL-6 and TNFα were significantly down-regulated by MSCs treatment. Our study suggest that MSCs treatment ameliorates DN via inhibition of MCP-1 expression by secreting HGF, thus reducing macrophages infiltration, down-regulating IL-1β, IL-6, TNFα expression in renal tissue in diabetic rats.
间充质干细胞(MSCs)治疗已被证明对糖尿病肾病(DN)有效。然而,MSCs 发挥肾保护作用的机制尚未得到明确证实。特别是,目前尚无研究探讨 MSCs 与糖尿病肾脏中的巨噬细胞之间的关系。为了研究 MSCs 对糖尿病肾病中巨噬细胞的影响,我们使用链脲佐菌素诱导糖尿病动物,连续两周通过尾静脉给予 MSCs(2×10(6))或不给予任何处理。治疗 8 周后,测量生理、生化和形态学参数。进行纤维连接蛋白(FN)、胶原 I、ED-1、单核细胞趋化蛋白-1(MCP-1)的免疫组织化学染色。通过实时逆转录聚合酶链反应和酶联免疫吸附试验分别测定促炎细胞因子和肝细胞生长因子(HGF)的基因和蛋白表达水平。MSCs 治疗后,血糖、尿白蛋白排泄、肌酐清除率显著降低。过碘酸希夫染色显示肾小球硬化,FN 和胶原 I 的表达也明显减弱。最重要的是,MSCs 治疗有效抑制了 MCP-1 的表达和肾脏浸润的巨噬细胞数量。MSCs 组 HGF 的表达上调。同时,MSCs 治疗显著下调了肾组织中 IL-1β、IL-6 和 TNFα 的表达。我们的研究表明,MSCs 通过分泌 HGF 抑制 MCP-1 的表达来改善 DN,从而减少巨噬细胞浸润,下调糖尿病大鼠肾组织中 IL-1β、IL-6、TNFα 的表达。